15

Asymptomatic PAAs in VQI
from 2010 to 2013

221 OPAR, 169 EPAR; OPAR patients had signiÔ¨Åcantly greater
MALE, loss of primary
MALE-free survival (95% vs 80%;
P < .001) and MALE-PODefree
patency, and MALEsurvival (93% vs